Navigation Links
World Alzheimer's Day 2008 Special Report: New Alzheimer Targets Take Center Stage
Date:9/24/2008

World Alzheimer's Day 2008 Special Report: New innovative treatment approaches in Alzheimer's disease which involve mechanisms other than a direct attack on amyloid plaques have emerged as the leading candidates in the fight against Alzheimer's in 2008. These approaches were presented at ICAD 2008, the world's leading forum on dementia research. These new developments are discussed in the debut of AlzheimerVideoNews.com, a new website which takes a critical look at the most important news in Alzheimer's research.

Los Angeles, CA (PRWEB) September 23, 2008 -- AlzheimerVideoNews.com debuts with a World Alzheimer's Day 2008 Special Report, discussing the most significant developments which occurred in 2008 in the field of Alzheimer's disease research. The new report, available in both a video news report and in print at http://www.AlzheimerVideoNews.com [AlzheimerVideoNews.com], discusses several innovative therapeutics which address emerging new targets in Alzheimer's disease. These new therapeutics have taken center stage in 2008, after the prominent failure of the anti-amyloid investigational drugs tramiprosate(Alzhemed®, Neurochem) and Flurizan® (Myriad Genetics).

The promising new therapeutic agents discussed at ICAD 2008, the world's leading forum on dementia research, and in scientific publications in 2008, included the antihistamine Dimebon® (Medivation, now licensed to Pfizer); Rember®, a reforumulation of methylene blue (TauRX Therapeutics of Singapore); and a novel, off-label method of perispinal administration of etanercept. These agents are all hypothesized to address non-amyloid targets, including the tau tangles found in the brain(Rember®).

Among these agents etanercept is unique, because it was designed to correct an abnormality in the immune system, identified in Alzheimer's disease, which may affect brain function. This abnormality, an excess of the molecule TNF in the cerebrospinal fluid, is hypothesized to interfere with brain cell communication in patients with Alzheimer's disease and related forms of dementia.

AlzheimerVideoNews.com takes a critical look at the most important news in Alzheimer's research. The http://www.AlzheimerVideoNews.com [AlzheimerVideoNews.com website] includes links to further reports and discussion regarding recent developments in Alzheimer's research. AlzheimerVideoNews.com is sponsored by http://www.nrimed.com [the Institute for Neurological Research, a private medical group, inc. in Los Angeles], which has developed the perispinal etanercept anti-TNF strategy for dementia.

References: Doody, R.S., S.I. Gavrilova, M. Sano, R.G. Thomas, P.S. Aisen, S.O. Bachurin, L. Seely, and D. Hung, Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet, 2008. 372(9634): p. 207-15.

Tobinick, E.L. and H. Gross, Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol, 2008. 8(1): p. 27.

###

Read the full story at http://www.prweb.com/releases/Alzheimers/etanercept/prweb1358314.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. (Report) World Privacy Forum Publishes Red Flag Rule Suggestions for Hospitals and Providers; New FTC-Enforced Rules Go Into Effect Nov. 1, Can Apply to Health Care Providers
2. New Lottery Ticket Envisions a World Free of MS
3. HTH Worldwide to Provide Mobile Healthcare Tool to HRG North Americas Affiliate Program
4. Kopernikus, observing our planet for a safer world
5. Substantial Second Quarter Surge for Angel MedFlight Worldwide Air Ambulance Services
6. WorldHeart Receives Favorable Decision to Continue NASDAQ Listing
7. Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes
8. Hurricane Ike: World Vision Readies Supplies, Staff, Volunteers for Response
9. IMRISneuro: The iMRI technology of choice among the worlds top ranked hospitals
10. ScentToSleep.com Is Pleased to Announce That the Company Was Featured in the September 15th Issue of Womans World Magazine
11. UNC receives record $181 million grant to evaluate health, poverty and gender programs worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
World Alzheimer's Day 2008 Special Report: New Alzheimer Targets Take Center Stage
(Date:1/20/2017)... ... 2017 , ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that ... Christina Austin - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains ... lens flare and light leak transitions have a very high-dynamic range for super smooth ...
(Date:1/20/2017)... ... ... a fine examination of how God handles sin, including how to let go of ... who, for over ten long years has been waiting to release this powerful insight about ... has been serving the Lord for over twenty years, and he has been preaching and ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “The Land of ... attention to the issue of world hunger, and shares the simple and achievable answer. ... devoted husband and member of the Fairview Missionary Church in Angola, Indiana where he ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... and facility enhancement of their 503A compounding pharmacy located in Ocala, Florida. ... of physicians and patients throughout the United States for high-quality human anti-aging ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound ... extension to RMT technology that delivers HD, dynamic, streaming ultrasound images and video ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase ... The global anti-obesity drugs market is expected to ... the forecast period and CAGR of 38.7% in the second half ... a CAGR of 32.8% from 2016 to 2027. The market is ... $24,063 million in 2027. ...
(Date:1/19/2017)... 2017  Sensus Healthcare, Inc. (NASDAQ: ... the treatment of non-melanoma skin cancers and other ... therapy, today announced that it will report its ... on Thursday, February 2, 2017 after the market close. ... call with the investment community on Thursday, February 2, ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... New Therapeutic Option to Address Motor Symptoms and ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... Fabrizio Stocchi , European Neurological Review,2016;11(Suppl. 2): 2-15, ...
Breaking Medicine Technology: